By NewsDesk @infectiousdiseasenews
In late December 2019, antibiotic development and commercialization company, Melinta Therapeutics, Inc. initiated a voluntary Chapter 11 process to effectuate restructuring transaction while continuing normal-course operations.
This caused a ripple effect of concern in the medical and public community. This followed just six months after Achaogen filed for bankruptcy.
In this video, I take a look at this important issue, some experts thoughts on how to address it and a Senate bill that hasn’t gone far in 6 months.
Infectious disease news brief: Monkeypox in Singapore
1 million STD cases daily across the globe
Nipah virus confirmed in Kerala, India
Congenital syphilis on the rise in the US: Tragic and Preventable!
PLAGUE in China: An update and review
SAMOA MEASLES OUTBREAK: ‘This epidemic has not yet peaked’
Dengue: ‘The rise in outbreaks this year is a wake-up call’
Measles in Japan 2019: Highest number of cases in years
One thought on “Antibiotic challenges and the Melinta situation”